Sep. 3 at 4:17 PM
$KLRS i mentioned this when it was
$2.30 area - but bears repeating
The company is focused on development of TH103, a novel, differentiated anti-VEGF investigational therapy. Developed by Dr. Napoleone Ferrara, TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina, whose team at Genentech in the 1980s was the first to isolate and clone vascular endothelial growth factor (VEGF)
If TH103 shows durability >12 weeks with comparable CST fluid reduction to aflibercept, it could easily support a
$500M–
$1.5B valuation, based on historical comps.
Markets often price in 25–50% of the total rNPV after strong Phase 1 data → that’s
$100M–
$150M uplift in market cap, or
$5–
$8/share upside (vs. KLRS ~
$2.50/share today).
In 2020, Kodiak Sciences (KOD) went from ~
$500M to
$3B+ market cap after Phase 1b durability data.
